NuVasive, Inc. (NASDAQ:NUVA) Director Lesley H. Howe sold 3,970 shares of NuVasive stock in a transaction on Friday, August 18th. The shares were sold at an average price of $64.64, for a total transaction of $256,620.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

NuVasive, Inc. (NASDAQ:NUVA) traded down 2.84% on Friday, hitting $64.06. 1,061,123 shares of the stock traded hands. NuVasive, Inc. has a 52 week low of $56.70 and a 52 week high of $81.68. The stock has a market cap of $3.25 billion, a price-to-earnings ratio of 100.88 and a beta of 1.06. The firm’s 50 day moving average is $72.65 and its 200 day moving average is $73.93.

NuVasive (NASDAQ:NUVA) last issued its quarterly earnings data on Thursday, July 27th. The medical device company reported $0.46 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.44 by $0.02. The company had revenue of $260.60 million for the quarter, compared to analyst estimates of $261.95 million. NuVasive had a net margin of 3.50% and a return on equity of 13.04%. The company’s revenue was up 10.3% on a year-over-year basis. During the same period in the prior year, the firm earned $0.40 earnings per share. Equities analysts anticipate that NuVasive, Inc. will post $2.00 earnings per share for the current year.

WARNING: “Lesley H. Howe Sells 3,970 Shares of NuVasive, Inc. (NUVA) Stock” was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this report on another publication, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/08/18/lesley-h-howe-sells-3970-shares-of-nuvasive-inc-nuva-stock.html.

Several brokerages recently commented on NUVA. Cowen and Company reiterated an “outperform” rating and issued a $85.00 target price on shares of NuVasive in a report on Monday, May 15th. Jefferies Group LLC reiterated a “buy” rating and issued a $84.00 target price on shares of NuVasive in a report on Friday, June 30th. Royal Bank Of Canada reiterated a “buy” rating and issued a $85.00 target price on shares of NuVasive in a report on Thursday, July 20th. Zacks Investment Research upgraded shares of NuVasive from a “sell” rating to a “hold” rating in a report on Tuesday, July 4th. Finally, TheStreet upgraded shares of NuVasive from a “c+” rating to a “b” rating in a report on Wednesday, May 3rd. Five investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $81.18.

Several institutional investors have recently modified their holdings of NUVA. Miles Capital Inc. raised its position in shares of NuVasive by 0.3% in the first quarter. Miles Capital Inc. now owns 3,118 shares of the medical device company’s stock valued at $233,000 after buying an additional 8 shares during the last quarter. Hanseatic Management Services Inc. raised its position in shares of NuVasive by 0.3% in the second quarter. Hanseatic Management Services Inc. now owns 14,868 shares of the medical device company’s stock valued at $1,144,000 after buying an additional 39 shares during the last quarter. Teacher Retirement System of Texas raised its position in shares of NuVasive by 1.0% in the second quarter. Teacher Retirement System of Texas now owns 4,040 shares of the medical device company’s stock valued at $311,000 after buying an additional 40 shares during the last quarter. US Bancorp DE raised its position in shares of NuVasive by 1.7% in the first quarter. US Bancorp DE now owns 2,401 shares of the medical device company’s stock valued at $180,000 after buying an additional 41 shares during the last quarter. Finally, Northwestern Mutual Investment Management Company LLC raised its position in shares of NuVasive by 0.5% in the first quarter. Northwestern Mutual Investment Management Company LLC now owns 8,720 shares of the medical device company’s stock valued at $651,000 after buying an additional 43 shares during the last quarter.

NuVasive Company Profile

Nuvasive, Inc is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process.

Insider Buying and Selling by Quarter for NuVasive (NASDAQ:NUVA)

Receive News & Ratings for NuVasive Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive Inc. and related companies with MarketBeat.com's FREE daily email newsletter.